These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35797897)

  • 1. Modulating the selectivity of inhibitors for prolyl oligopeptidase inhibitors and fibroblast activation protein-α for different indications.
    Plescia J; Hédou D; Pousse ME; Labarre A; Dufresne C; Mittermaier A; Moitessier N
    Eur J Med Chem; 2022 Oct; 240():114543. PubMed ID: 35797897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated Synthetic, Biophysical, and Computational Investigations of Covalent Inhibitors of Prolyl Oligopeptidase and Fibroblast Activation Protein α.
    Plescia J; De Cesco S; Patrascu MB; Kurian J; Di Trani J; Dufresne C; Wahba AS; Janmamode N; Mittermaier AK; Moitessier N
    J Med Chem; 2019 Sep; 62(17):7874-7884. PubMed ID: 31393718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting inhibition of fibroblast activation protein-α and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments.
    Christiansen VJ; Jackson KW; Lee KN; Downs TD; McKee PA
    Neoplasia; 2013 Apr; 15(4):348-58. PubMed ID: 23555181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of covalent prolyl oligopeptidase boronic ester inhibitors.
    Plescia J; Dufresne C; Janmamode N; Wahba AS; Mittermaier AK; Moitessier N
    Eur J Med Chem; 2020 Jan; 185():111783. PubMed ID: 31732257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Covalent Inhibition of Prolyl Oligopeptidase (POP): Discovery of Sulfonylfluoride Peptidomimetics.
    Guardiola S; Prades R; Mendieta L; Brouwer AJ; Streefkerk J; Nevola L; Tarragó T; Liskamp RMJ; Giralt E
    Cell Chem Biol; 2018 Aug; 25(8):1031-1037.e4. PubMed ID: 29779956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of tumor growth in mice by rationally designed pseudopeptide inhibitors of fibroblast activation protein and prolyl oligopeptidase.
    Jackson KW; Christiansen VJ; Yadav VR; Silasi-Mansat R; Lupu F; Awasthi V; Zhang RR; McKee PA
    Neoplasia; 2015 Jan; 17(1):43-54. PubMed ID: 25622898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of the substrate preferences of two post-proline cleaving endopeptidases, prolyl oligopeptidase and fibroblast activation protein α.
    Jambunathan K; Watson DS; Endsley AN; Kodukula K; Galande AK
    FEBS Lett; 2012 Jul; 586(16):2507-12. PubMed ID: 22750443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low molecular weight inhibitors of Prolyl Oligopeptidase: a review of compounds patented from 2003 to 2010.
    López A; Tarragó T; Giralt E
    Expert Opin Ther Pat; 2011 Jul; 21(7):1023-44. PubMed ID: 21539473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase.
    Poplawski SE; Lai JH; Li Y; Jin Z; Liu Y; Wu W; Wu Y; Zhou Y; Sudmeier JL; Sanford DG; Bachovchin WW
    J Med Chem; 2013 May; 56(9):3467-77. PubMed ID: 23594271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3-Oxo-hexahydro-1H-isoindole-4-carboxylic Acid as a Drug Chiral Bicyclic Scaffold: Structure-Based Design and Preparation of Conformationally Constrained Covalent and Noncovalent Prolyl Oligopeptidase Inhibitors.
    Mariaule G; De Cesco S; Airaghi F; Kurian J; Schiavini P; Rocheleau S; Huskić I; Auclair K; Mittermaier A; Moitessier N
    J Med Chem; 2016 May; 59(9):4221-34. PubMed ID: 26619267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of novel chemical scaffolds targeting prolyl oligopeptidase for neurological therapeutics.
    Kumar R; Parameswaran S; Bavi R; Baek A; Son M; Rampogu S; Park C; Lee G; Zeb A; Parate S; Rana RM; Lee KW
    J Mol Graph Model; 2019 May; 88():92-103. PubMed ID: 30665156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity.
    Ryabtsova O; Jansen K; Van Goethem S; Joossens J; Cheng JD; Lambeir AM; De Meester I; Augustyns K; Van der Veken P
    Bioorg Med Chem Lett; 2012 May; 22(10):3412-7. PubMed ID: 22525314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolyl oligopeptidase and its role in the organism: attention to the most promising and clinically relevant inhibitors.
    Babkova K; Korabecny J; Soukup O; Nepovimova E; Jun D; Kuca K
    Future Med Chem; 2017 Jun; 9(10):1015-1038. PubMed ID: 28632451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery.
    Rosenblum JS; Kozarich JW
    Curr Opin Chem Biol; 2003 Aug; 7(4):496-504. PubMed ID: 12941425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationship and biochemical evaluation of novel fibroblast activation protein and prolyl endopeptidase inhibitors with α-ketoamide warheads.
    Šimková A; Ormsby T; Sidej N; Slavětínská LP; Brynda J; Beranová J; Šácha P; Majer P; Konvalinka J
    Eur J Med Chem; 2021 Nov; 224():113717. PubMed ID: 34371463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Human Prolyl Oligopeptidase Activity by the Cyclotide Psysol 2 Isolated from Psychotria solitudinum.
    Hellinger R; Koehbach J; Puigpinós A; Clark RJ; Tarragó T; Giralt E; Gruber CW
    J Nat Prod; 2015 May; 78(5):1073-82. PubMed ID: 25894999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2-antiplasmin.
    Lee KN; Jackson KW; Christiansen VJ; Dolence EK; McKee PA
    J Thromb Haemost; 2011 May; 9(5):987-96. PubMed ID: 21251197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constrained peptidomimetics reveal detailed geometric requirements of covalent prolyl oligopeptidase inhibitors.
    Lawandi J; Toumieux S; Seyer V; Campbell P; Thielges S; Juillerat-Jeanneret L; Moitessier N
    J Med Chem; 2009 Nov; 52(21):6672-84. PubMed ID: 19888757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis.
    Tenorio-Laranga J; Coret-Ferrer F; Casanova-Estruch B; Burgal M; García-Horsman JA
    J Neuroinflammation; 2010 Apr; 7():23. PubMed ID: 20370893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mRNA, protein levels, and enzymatic activity.
    Myöhänen TT; García-Horsman JA; Tenorio-Laranga J; Männistö PT
    J Histochem Cytochem; 2009 Sep; 57(9):831-48. PubMed ID: 19687473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.